Inflammation is associated with adverse cardiovascular events. Data from recent trials suggest that colchicine reduces the risk of cardiovascular events. In this multicenter trial with a 2-by-2 ...

Highlighted text has been updated as of November 17, 2024. The CLEAR SYNERGY (OASIS 9) trial showed that in patients with acute MI undergoing PCI, daily treatment with colchicine did not reduce MACE ...

WASHINGTON — Colchicine does not protect against major cardiovascular adverse events after an acute myocardial infarction, according to a multinational placebo-controlled trial of more than 7000 ...

WASHINGTON, DC—The routine use of colchicine, an anti-inflammatory agent with a challenging side-effect profile, fails to reduce the risk of major adverse cardiovascular events when used in patients ...

Get detailed information on Colchicine, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

Both acute and long-term colchicine use to treat patients with acute myocardial infarction (MI) did not reduce cardiovascular death, myocardial infarction, stroke or ischemia-driven revascularization, ...

Barton, Cook and Loudon, J. Chem. Soc., 176 (1945). Cook, Dickson and Loudon, J. Chem. Soc., 746 (1947).

In the cited meta-analysis, colchicine was associated with reduced risk of treatment failure (OR: 0.23) and recurrent pericarditis (OR: 0.39), but with a trend toward more adverse effects.

The names given to these diseases do not follow any systematic guidelines, and sometimes the same disorder carries several names. The aim of this study is to refine the definition of AIDs and to ...

Field trials in plant biotechnology are designed to test promising new plants in a situation similar to the actual growing conditions by farmers, such as unpredictable light and temperature, the ...

From the Department of Cardiology and Angiology I, University Heart Center Freiburg, Germany (D.W.) Faculty of Medicine, University of Freiburg, Germany (D.W.) K. Ley has received research funding for ...

Percutaneous coronary intervention (PCI) is currently the main method for treating coronary artery stenosis, but the incidence of restenosis after PCI is relatively high. Restenosis, the narrowing of ...